• Je něco špatně v tomto záznamu ?

Radiofrequency induced hyperthermia in non-muscle invasive bladder cancer: Oncologic outcomes in a real-world scenario

S. Mero, K. Oberneder, J. Weiss, E. Grobet-Jeandin, A. Grégoris, P. Sèbe, S. Shariat, D. D'Andrea

. 2025 ; 49 (5) : 501746. [pub] 20250317

Jazyk xxx, angličtina Země Španělsko

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015528

OBJECTIVES: Patients with non-muscle invasive bladder cancer (NMIBC) face a high risk of recurrence and progression after transurethral resection, making adjuvant therapies necessary. Intravesical device-assisted therapies, such as radiofrequency-induced thermochemotherapy (RITE), have shown promise in enhancing the effectiveness of intravesical chemotherapies. This study aimed to evaluate oncological outcomes in patients with NMIBC treated with RITE in a real-world setting, encompassing those unresponsive to prior Bacillus Calmette-Guérin (BCG) or intravesical chemotherapy, as well as those who declined or were ineligible for BCG or radical cystectomy (RC). METHODS: A retrospective multicenter analysis of patients treated with RITE for NMIBC between 2015 and 2024 was performed. Co-primary endpoints of the study were intravesical recurrence free survival (RFS) and high-grade intravesical recurrence free survival (HG-RFS). Secondary endpoints included radical cystectomy-free survival (RC-FS), overall survival (OS), cancer-specific survival (CSS), and adverse events (AEs). RESULTS: Fifty-nine consecutive patients were included in the final analyses. Overall, 12 (20%) and 45 (76%) patients failed previous intravesical chemotherapy, and immunotherapy with BCG, respectively. The 24-months RFS and HG-RFS following RITE were 68.6% (95% CI: 0.568, 0.828) and 74.8% (95% CI: 0.632, 0.885). RC-FS at 24 months was 93.8% (95% CI: 0.872, 1.000). The OS probability at 24 months was 91%, with a CSS of 97.8%. Most common AEs were dysuria and urgency in 27 (45.7%) patients, treatment limiting bladder spasms in 11 (19%) patients, low bladder compliance in 11 (19%) patients and urethral strictures in 5 (8%) patients. CONCLUSION: In our analyses, RITE resulted in notable antitumor activity and allows for the avoidance of more aggressive and quality-of-life-limiting therapies, such as radical cystectomy. RITE might be considered as a second-line bladder-sparing option in patients failing previous intravesical therapies. Long-term follow-up and larger-scale data are required to validate our findings.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015528
003      
CZ-PrNML
005      
20250731091042.0
007      
ta
008      
250708s2025 sp f 000 0|eng s
009      
AR
024    7_
$a 10.1016/j.acuroe.2025.501746 $2 doi
035    __
$a (PubMed)40107614
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng spa
044    __
$a sp
100    1_
$a Mero, S $u Departamento de Urología, Universidad de Medicina de Viena, Viena, Austria. Electronic address: sascha.mero@meduniwien.ac.at
245    10
$a Radiofrequency induced hyperthermia in non-muscle invasive bladder cancer: Oncologic outcomes in a real-world scenario / $c S. Mero, K. Oberneder, J. Weiss, E. Grobet-Jeandin, A. Grégoris, P. Sèbe, S. Shariat, D. D'Andrea
520    9_
$a OBJECTIVES: Patients with non-muscle invasive bladder cancer (NMIBC) face a high risk of recurrence and progression after transurethral resection, making adjuvant therapies necessary. Intravesical device-assisted therapies, such as radiofrequency-induced thermochemotherapy (RITE), have shown promise in enhancing the effectiveness of intravesical chemotherapies. This study aimed to evaluate oncological outcomes in patients with NMIBC treated with RITE in a real-world setting, encompassing those unresponsive to prior Bacillus Calmette-Guérin (BCG) or intravesical chemotherapy, as well as those who declined or were ineligible for BCG or radical cystectomy (RC). METHODS: A retrospective multicenter analysis of patients treated with RITE for NMIBC between 2015 and 2024 was performed. Co-primary endpoints of the study were intravesical recurrence free survival (RFS) and high-grade intravesical recurrence free survival (HG-RFS). Secondary endpoints included radical cystectomy-free survival (RC-FS), overall survival (OS), cancer-specific survival (CSS), and adverse events (AEs). RESULTS: Fifty-nine consecutive patients were included in the final analyses. Overall, 12 (20%) and 45 (76%) patients failed previous intravesical chemotherapy, and immunotherapy with BCG, respectively. The 24-months RFS and HG-RFS following RITE were 68.6% (95% CI: 0.568, 0.828) and 74.8% (95% CI: 0.632, 0.885). RC-FS at 24 months was 93.8% (95% CI: 0.872, 1.000). The OS probability at 24 months was 91%, with a CSS of 97.8%. Most common AEs were dysuria and urgency in 27 (45.7%) patients, treatment limiting bladder spasms in 11 (19%) patients, low bladder compliance in 11 (19%) patients and urethral strictures in 5 (8%) patients. CONCLUSION: In our analyses, RITE resulted in notable antitumor activity and allows for the avoidance of more aggressive and quality-of-life-limiting therapies, such as radical cystectomy. RITE might be considered as a second-line bladder-sparing option in patients failing previous intravesical therapies. Long-term follow-up and larger-scale data are required to validate our findings.
650    _2
$a lidé $7 D006801
650    12
$a nádory močového měchýře $x terapie $x patologie $x mortalita $7 D001749
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    _2
$a invazivní růst nádoru $7 D009361
650    _2
$a lidé středního věku $7 D008875
650    _2
$a výsledek terapie $7 D016896
650    12
$a indukovaná hypertermie $x metody $7 D006979
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a cystektomie $7 D015653
650    _2
$a nádory močového měchýře neinvadující svalovinu $7 D000093284
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Oberneder, K $u Departamento de Urología, Universidad de Medicina de Viena, Viena, Austria
700    1_
$a Weiss, J $u Departamento de Urología, Universidad de Medicina de Viena, Viena, Austria
700    1_
$a Grobet-Jeandin, E $u División de Urología, Hospitales Universitarios de Ginebra, Ginebra, Switzerland
700    1_
$a Grégoris, A $u División de Urología, Hospitales Universitarios de Ginebra, Ginebra, Switzerland
700    1_
$a Sèbe, P $u División de Urología, Hospitales Universitarios de Ginebra, Ginebra, Switzerland
700    1_
$a Shariat, S $u Departamento de Urología, Universidad de Medicina de Viena, Viena, Austria; Comprehensive Cancer Center, Universidad de Medicina de Viena, Viena, Austria; Instituto de Urología y Andrología Karl Landsteiner, Viena, Austria; Deparatmento de Urología, Segunda Facultad de Medicina, Universidad Carolina, Praga, Czechia; División de Urología, Centro Hourani de Investigación Científica Aplicada, Universidad Al-Ahliyya Amman, Amman, Jordan; Departamento de Urología, Weill Cornell Medical College, Nueva York, NY, United States; Departamento de Urología, Universidad de Texas Southwestern, Dallas, TX, United States
700    1_
$a D'Andrea, D $u Departamento de Urología, Universidad de Medicina de Viena, Viena, Austria
773    0_
$w MED00208706 $t Actas urologicas españolas $x 2173-5786 $g Roč. 49, č. 5 (2025), s. 501746
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40107614 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091036 $b ABA008
999    __
$a ok $b bmc $g 2366398 $s 1252653
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 49 $c 5 $d 501746 $e 20250317 $i 2173-5786 $m Actas urologicas españolas $n Actas Urol Esp (Engl Ed) $x MED00208706
LZP    __
$a Pubmed-20250708
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace